Jeremy Nighohossian is a senior fellow and economist at the Competitive Enterprise Institute, focusing on health care policy. His expertise is in healthcare antitrust and regulation including Certificate of Need regulations and competition and federal and state reimbursement policies. Jeremy writes on how government regulation and dominance of the healthcare sector stifle innovation, reduce quality, and raise costs.
Jeremy holds a Ph.D. in economics from Texas A&M University and a B.S. in Chemical Engineering from the University of Illinois. Before joining CEI, he worked at the Center for Healthcare Economics and Policy at FTI Consulting where he specialized in anti-trust and disputes in healthcare working on several projects with Compass Lexecon. While at FTI, Dr. Nighohossian built a policy analysis practice where he conducted analyses of state and national healthcare policies. Jeremy’s expertise has taken him around the world, testifying to the South Africa Competition Commission on hospital prices and how they relate to supply and he helped design a value-based payment system in the UK.
Authored by Jeremy Nighohossian
News
Inflation increases again in September, no relief in sight for consumers’ wallets: CEI analysis
September’s Consumer Price Index report shows a 0.6 percent increase in prices across all sectors, up from a 0.4 percent increase in August.
FDA deserves credit for approval pancreatic cancer drug
The FDA on August 26 approved a new breakthrough drug to treat pancreatic cancer. CEI Senior Fellow and Economist Jeremy Nighohossian praised…
FDA succeeds in approving new flu vaccine: CEI comment
The FDA has approved a flu vaccine made with mRNA technology, the same technology used for Moderna’s COVID-19 vaccine, the company announced on…
Blog
How the Medicaid provider taxes raise your premiums
One of the major provisions of the One Big Beautiful Bill (OBBB) was to arrest the growth of provider taxes. Provider taxes are specific…
This week in health care policy: November 6-13
Drug pricing and innovation Biotech groups sue CMS over the GLOBE model. Three biotech groups sued CMS over the Global…
This week in health care policy: October 31-November 6, 2026
Drug pricing and PBMs Medicare’s second round of negotiated prices starts in two months. On January 1, negotiated prices for…
Op-Eds/Articles
Arcamax
Commentary: House Democrats have big (government) plans for health care
Now that Democrats have regained control of the House, they will likely embark on a mission to expand government in the name of making…
The Hill
Make some medications more affordable by cutting one piece of red tape
One piece of red tape is keeping the prices of critical medications too high. These medicines treat autoimmune diseases, diabetes, cancer, and certain other…
The Wall Street Journal
Don’t Expand Payroll Taxes for Social Security
In his column “Republicans’ Pre-Emptive Social Security Surrender” (Political Economics, Sept. 18), Joseph C. Sternberg makes a persuasive argument against expanding…
Studies
A Free Market is the Best Medicine
Introduction The pharmaceutical supply market is seeing extraordinarily high levels of innovation and consumer-benefiting evolution. The combination of a competitive market for generic drugs,…
I, Pharmaceutical
The global pharmaceutical industry is complex. This is true not only in the number of countries involved but the range of products, the sets…
Citations
World Radio
WORLD Radio – Drug deals
CEI’s Jeremy Nighohossian was interviewed by World on their World Radio – Drug deals segment regarding pharmacy benefit managers and new federal regulations regarding…
The National News Desk
Inflation surges as Iran war drives prices higher across economy
CEI’s Jeremy Nighohossian was quoted in The National News Desk regarding CPI figures from September 2026. Core prices, which exclude food and energy,…
The Epoch Times
Feds Aim to Tighten Drug Payment Loophole, Save Taxpayers Billions
CEI expert Jeremy Nighohossian was cited by the Epoch Times in their explanation of rule 340b in hospitals. Large hospitals are able to…
Regulatory Comments
CEI Comments on 340B Payment Change
The Competitive Enterprise Institute (CEI) submits these comments in support of several of the provisions in the rule recently proposed by CMS. Founded in…
CEI Comments on Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program
Comments of the Competitive Enterprise Institute Dear Dr. Oz, The Competitive Enterprise Institute (CEI) submits these comments in support of several provisions…
CEI Comments on Global Benchmark for Efficient Drug Pricing (GLOBE) Model
Comments of the Competitive Enterprise Institute Dear Dr. Oz, The Competitive Enterprise Institute (CEI) submits these comments in opposition to the creation…
Podcast Episodes
Obamacare Problems with Jeremy Nighohossian
This week we talk about the unintended consequences of the Sarbanes-Oxley Act of 2002, decarbonization of economic growth, and resources for reporting government corruption at...